ELF3-AS1: A Potential Drug Target and Biomarker (G102723465)
ELF3-AS1: A Potential Drug Target and Biomarker
The endogenous RNA regulatory system plays a crucial role in maintaining cellular homeostasis, and dysregulation of this system has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and systemic inflammatory disorders. One of the key components of the endogenous RNA regulatory system is the mRNA target of the ELF3 gene, ELF3-AS1.
ELF3 (endogenous RNA-binding protein 3) is a non-coding RNA molecule that plays a critical role in regulating gene expression and has been shown to participate in various cellular processes, including cell growth, apoptosis, and translation of RNA into protein. The ELF3 gene has four splice variants, ELF3-AS1, ELF3-AS2, ELF3-AS3, and ELF3-AS4, and each of these variants has distinct differences in its expression level and function.
ELF3-AS1 is a 24.1-kcal RNA molecule that contains 194 amino acid residues and is expressed in various tissues and cell types. It is highly conserved in its sequence and has been shown to play a critical role in regulating gene expression. Studies have shown that ELF3-AS1 can interact with various protein partners, including the protein encoded by the PDGF-AA gene, which is a potent regulator of cell growth and survival.
In addition to its role in regulating gene expression, ELF3-AS1 has also been shown to play a critical role in cellular signaling pathways. It has been shown to be involved in the regulation of cell adhesion, migration, and the development of cancer. For example, ELF3-AS1 has been shown to play a critical role in the regulation of cancer cell migration and the development of neuroblastoma.
As a potential drug target, ELF3-AS1 has been identified as a promising target for small molecule inhibitors. Studies have shown that the small molecule inhibitor, NEDD8, can inhibit the expression of ELF3-AS1 and reduce the levels of its protein product. This inhibition of ELF3-AS1 has been shown to result in a variety of cellular and molecular changes, including a decrease in cell growth, a reduction in the formation of new blood vessels, and a decrease in the production of neuroblastoma.
In addition to its potential as a drug target, ELF3-AS1 has also been shown to be a potential biomarker for a variety of diseases. For example, it has been shown to be involved in the regulation of cancer cell growth and has been used as a biomarker for the diagnosis and prognosis of various cancers, including neuroblastoma, breast cancer, and lung cancer.
The identification of ELF3-AS1 as a potential drug target and biomarker has significant implications for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of ELF3-AS1 in cellular and molecular processes and to develop effective small molecule inhibitors of its activity.
In conclusion, ELF3-AS1 is a non-coding RNA molecule that plays a critical role in regulating gene expression and has been shown to participate in various cellular processes. Its potential as a drug target and biomarker makes it an attractive target for small molecule inhibitors, and further research is needed to fully understand its role in cellular and molecular processes and to develop effective treatments for a variety of diseases.
Protein Name: ELF3 Antisense RNA 1
The "ELF3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELF3-AS1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1 | EMX2 | EMX2OS | EN1 | EN2 | ENAH | ENAM | ENC1 | ENDOD1 | ENDOG | Endogenous Retrovirus group K Env polyprotein (ERVK) | Endogenous retrovirus group K member 25 Pol protein-like, transcript variant X1 | EndoGlyx-1 | Endoplasmic reticulum collagen prolyl 3-hydroxylation complex | Endothelin receptor | Endothelin-Converting Enzymes (ECE) | Endothiapepsin | ENDOU
